Abstract
Despite the exceedingly high cardiovascular risk in hemodialysis patients, it is uncertain whether statin regimens lead to clinical benefit in this population. KDIGO (Kidney Disease Improving Global Outcomes) guidelines summarize the evidence, stating that initiation of statin treatment is not recommended for most prevalent hemodialysis patients. Since the 4D and AURORA trials did not cover all age and risk ranges, an individualized treatment approach is accepted. Thus, patients and physicians may reasonably choose statin treatment if they are interested in an apparent, but relatively small, uncertain reduction in cardiovascular events. Since very high low-density lipoprotein cholesterol might increase the likelihood of benefit from statins in a dialysis patient, patients who meet this criterion may be more inclined to receive a statin. Other factors that might influence a patient’s decision to receive statins could include more severe comorbidity or higher current pill burden—both favoring non-treatment––and recent myocardial infarction or greater life expectancy—both favoring treatment. The latter may be especially true for dialysis patients inJapan.
Similar content being viewed by others
References
Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.
Wanner C, Krane V. Sunrise of statins after AURORA and 4D? J Am Soc Nephrol. 2011;22:1184–6.
Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.
Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–75.
Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:251–62.
Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34:1807–17.
März W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316–25.
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, CORONA group, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Gissi-HF Investigators, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–9.
Ridker PM, Wilson PWF. A trial-based approach to statin guidelines. JAMA. 2013;310:1123–4.
Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, Komuro I, on behalf of the PEARL Study Investigators. Effects of pitavastatin on Japanese patients with chronic heart failure: the Pitavastatin heart failure study (PEARL study). Circ J. 2013;77:917–25.
Kihara Y. Statin therapy in chronic heart failure. Circ J. 2013;77:895–7.
Koya D, Campese V. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atherosclerol Thromb. 2013;20:407–21.
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013;3:1–46.
Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206:512–7.
Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:1112–20.
Conflict of interest
CW has received honoraria and travel support from Merck Sharp & Dohme, Pfizer and Astellas for lecturing at congresses. KRS and VK do not report conflicts.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the German diabetes and dialysis study investigators.
About this article
Cite this article
Wanner, C., Schmidt, KR. & Krane, V. Results of the 4D study: ten years of follow-up? . Clin Exp Nephrol 18, 274–277 (2014). https://doi.org/10.1007/s10157-013-0888-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-013-0888-3